Bristol-Myers Squibb Company (BMY) Q3 2022 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 0.3%

Bristol Myers Squibb reported better-than-expected earnings per share, which reflects positively on their operational efficiency. However, the stock fell slightly by 0.3%, indicating that investors may have been looking for more comprehensive guidance or revenue figures. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.99	N/A	+8.80%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

We are pleased with our EPS performance this quarter.

Our focus remains on delivering innovative treatments to patients.

Bristol Myers Squibb Beats on EPS, Stock Down 0.3%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 0.3%

Key numbers

Management commentary